Drug Trial Radar · NCT06168383
To Evaluate the Efficacy and Safety of HSK31679 in Chinese Patients With Non-Alcoholic Steatohepatitis (NASH) .
Last checked: Nov 20, 2026Latest source record: Jun 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
186
Actual
Start
Jan 5, 2024
Primary completion
Dec 12, 2025
Study completion Jan 16, 2026
Sponsor
- Lead sponsor
- Haisco Pharmaceutical Group Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Dec 13, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A double-blind placebo controlled, randomized, Phase 2b study to evaluate the efficacy and safety of once-daily, oral administration of 80 or 160 mg HSK31679 versus matching placebo in Patients With Non-Alcoholic Steatohepatitis (NASH) and Fibrosis.
Conditions
- Non-Alcoholic Steatohepatitis (NASH)
Interventions
HSK31679 80mgDrug
once daily, oral administration of HSK31679 80mg from Day 1 to Week 52.
HSK31679 160mgDrug
once daily, oral administration of HSK31679 160mg from Day 1 to Week 52.
PlaceboDrug
once daily, oral administration of placebo from Day 1 to Week 52.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportions of patients(HSK31679-treated versus placebo-treated) with NASH improvement and with no worsening of fibrosis at week 52 compared with Baseline.Time frame: from Baseline to 52 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Beijing Tsinghua Changgung Hospital, Tsinghua University
Beijing, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.